Abdalian replaces Rogers as CFO at BG Medicine
This article was originally published in Clinica
Executive Summary
BG Medicine, a company developing novel cardiovascular diagnostics, has appointed Charles Abdalian executive vice-president and CFO, replacing Michael Rogers who is leaving the company. Mr Abdalian has over 30 years' experience in healthcare corporate finance and strategic management, having most recently served as vice-president and CFO of Knome, a bioinformatics company.
You may also be interested in...
Iron off the tee as Takeda rolls out Rienso in EU
Takeda has launched Rienso (ferumoxytol), a new option for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) in the UK, after having been granted marketing authorization by the European Commission in June. This is the start of the product’s European roll out.
Joyce Frey-Vasconcells joins Aastrom SAB
Aastrom Biosciences, a company developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe chronic cardiovascular diseases, has appointed Dr Joyce Frey-Vasconcells to its scientific advisory board. Dr Frey-Vasconcells is founder and president of Frey-Vasconcells Consulting and previously served as a regulatory consultant for Pharmanet. Prior to that, she spent more than 12 years at the FDA as deputy director, Office of Cellular, Tissue and Gene Therapies with the Center for Biologics Evaluation and Research.
Itin, Chiswell and Davis recruited to Kymab board
Kymab, a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs has appointed Christian Itin, David Chiswell and Richard Davis to its board as non-executive directors. Dr Itin was recently appointed CEO and chair of the board at Cytos Biotechnology, having previously served as Micromet's president and CEO. Dr Chiswell currently serves as chair of Nabriva Therapeutics and Albireo Pharma and previously served as CEO of Nabriva Therapeutics.